<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes</journal-id><journal-id journal-id-type="hwp">diabetes</journal-id><journal-id journal-id-type="pmc">diabetes</journal-id><journal-id journal-id-type="publisher-id">Diabetes</journal-id><journal-title-group><journal-title>Diabetes</journal-title></journal-title-group><issn pub-type="ppub">0012-1797</issn><issn pub-type="epub">1939-327X</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19509020</article-id><article-id pub-id-type="pmc">2731524</article-id><article-id pub-id-type="publisher-id">0382</article-id><article-id pub-id-type="doi">10.2337/db09-0382</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Complications</subject></subj-group></subj-group></article-categories><title-group><article-title>Effects of Differing Antecedent Increases of Plasma Cortisol on Counterregulatory Responses During Subsequent Exercise in Type 1 Diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bao</surname><given-names>Shichun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Briscoe</surname><given-names>Vanessa J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tate</surname><given-names>Donna B.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Stephen N.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><aff id="aff1"><sup>1</sup>Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee; </aff><aff id="aff2"><sup>2</sup>Veterans Administration Hospital, Nashville, Tennessee.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Stephen N. Davis, <email>steve.davis@vanderbilt.edu</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>9</day><month>6</month><year>2009</year></pub-date><volume>58</volume><issue>9</issue><fpage>2100</fpage><lpage>2108</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>27</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 by the American Diabetes Association.</copyright-statement><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zdb00909002100.pdf"/><abstract><sec><title>OBJECTIVE</title><p>Antecedent hypoglycemia can blunt neuroendocrine and autonomic nervous system responses to next-day exercise in type 1 diabetes. The aim of this study was to determine whether antecedent increase of plasma cortisol is a mechanism responsible for this finding.</p></sec><sec><title>RESEARCH DESIGN AND METHODS</title><p>For this study, 22 type 1 diabetic subjects (11 men and 11 women, age 27 &#x000b1; 2 years, BMI 24 &#x000b1; 1 kg/m<sup>2</sup>, A1C 7.9 &#x000b1; 0.2%) underwent four separate randomized 2-day protocols, with overnight normalization of blood glucose. Day 1 consisted of morning and afternoon 2-h hyperinsulinemic- (9 pmol &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>) euglycemic clamps (5.1 mmol/l), hypoglycemic clamps (2.9 mmol/l), or euglycemic clamps with a physiologic low-dose intravenous infusion of cortisol to reproduce levels found during hypoglycemia or a high-dose infusion, which resulted in further twofold greater elevations of plasma cortisol. Day 2 consisted of 90-min euglycemic cycling exercise at 50% <italic>V</italic><sc>o</sc><sub>2max</sub>.</p></sec><sec><title>RESULTS</title><p>During exercise, glucose levels were equivalently clamped at 5.1 &#x000b1; 0.1 mmol/l and insulin was allowed to fall to similar levels. Glucagon, growth hormone, epinephrine, norepinephrine, and pancreatic polypeptide responses during day 2 exercise were significantly blunted following antecedent hypoglycemia, low- and high-dose cortisol, compared with antecedent euglycemia. Endogenous glucose production and lipolysis were also significantly reduced following day 1 low- and high-dose cortisol.</p></sec><sec><title>CONCLUSIONS</title><p>Antecedent physiologic increases in cortisol (equivalent to levels occurring during hypoglycemia) resulted in blunted neuroendocrine, autonomic nervous system, and metabolic counterregulatory responses during subsequent exercise in subjects with type 1 diabetes. These data suggest that prior elevations of cortisol may play a role in the development of exercise-related counterregulatory failure in those with type 1 diabetes.</p></sec></abstract><funding-group><award-group><funding-source id="CS100">National Institutes of Health</funding-source><award-id rid="CS100">HL056693</award-id><award-id rid="CS100">DK069803</award-id></award-group></funding-group></article-meta></front><body><p>The Diabetes Control and Complications Trial has definitively demonstrated that intensive glycemic control can reduce microvascular complications in those with type 1 diabetes (<xref ref-type="bibr" rid="B1">1</xref>). However, intensive therapy is associated with an increased incidence of hypoglycemia (<xref ref-type="bibr" rid="B2">2</xref>). Exercise is a cornerstone of diabetes management. It improves insulin sensitivity, helps in body weight maintenance, and lowers the risk of cardiovascular disease. Unfortunately, exercise is associated with an increased prevalence of hypoglycemia in patients with diabetes. Furthermore, fear of hypoglycemia results in a serious limitation to the widespread implementation of intensive glycemic control and exercise.</p><p>Previous studies have shown that antecedent hypoglycemia can blunt neuroendocrine, autonomic nervous system (ANS), and metabolic counterregulatory responses to subsequent exercise (<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>). Reciprocally, antecedent exercise can also blunt homeostatic counterregulatory responses to subsequent hypoglycemia (<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>). Therefore, vicious cycles can be created in type 1 diabetes where an episode of hypoglycemia or exercise can downregulate counterregulatory responses to a subsequent episode of either stress, thereby increasing the risk for further hypoglycemia. However, the mechanisms responsible for exercise-associated counterregulatory failure are not known. Multiple studies have demonstrated that antecedent increases of corticosteroids can blunt subsequent ANS and neuroendocrine responses to a wide spectrum of differing antecedent stress (<xref ref-type="bibr" rid="B7">7</xref><xref ref-type="bibr" rid="B8"/><xref ref-type="bibr" rid="B9"/><xref ref-type="bibr" rid="B10"/><xref ref-type="bibr" rid="B11"/><xref ref-type="bibr" rid="B12"/><xref ref-type="bibr" rid="B13"/><xref ref-type="bibr" rid="B14"/><xref ref-type="bibr" rid="B15"/><xref ref-type="bibr" rid="B16"/><xref ref-type="bibr" rid="B17"/><xref ref-type="bibr" rid="B18"/><xref ref-type="bibr" rid="B19"/><xref ref-type="bibr" rid="B20"/>&#x02013;<xref ref-type="bibr" rid="B21">21</xref>). Previous studies have also demonstrated that pharmacologic antecedent increases of cortisol can blunt counterregulatory responses to subsequent hypoglycemia in normal subjects (a stress that defends against a falling plasma glucose with similar counterregulatory responses compared with exercise) (<xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B8">8</xref>). Although, the question of whether physiologic levels of cortisol can blunt counterregulatory responses to subsequent hypoglycemia is still undecided (<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B22">22</xref><xref ref-type="bibr" rid="B23"/>&#x02013;<xref ref-type="bibr" rid="B24">24</xref>). However, studies specifically investigating the effects of prior elevations of corticosteroids on counterregulatory mechanisms during exercise are lacking. Furthermore, no study has investigated the mechanisms responsible for exercise-related counterregulatory failure in the clinically relevant group of those with type 1 diabetes.</p><p>Therefore, the specific aim of this present study was to test the hypothesis that antecedent physiologic or pharmacologic elevations of cortisol could blunt counterregulatory responses during subsequent submaximal exercise in type 1 diabetic individuals. To test this hypothesis, hydrocortisone was administered intravenously on day 1 during hyperinsulinemic-euglycemic clamps and responses to subsequent euglycemic exercise were studied during the following day.</p><sec><title>RESEARCH DESIGN AND METHODS</title><p>We studied 22 patients with type 1 diabetes (11 men and 11 women), age 27 &#x000b1; 2 years, BMI 24 &#x000b1; 1 kg/m<sup>2</sup>, and A1C 7.9 &#x000b1; 0.2% (normal range 4&#x02013;6.5%). Patients had been diagnosed with type 1 diabetes for 12 &#x000b1; 2 years and had no clinical evidence of tissue complications of the disease such as retinopathy, renal impairment, or autonomic neuropathy. Patients were treated with either multiple daily injections of insulin or continuous subcutaneous insulin via a pump. Each patient had normal blood count, plasma electrolytes, and liver function. All gave written informed consent. Studies were approved by the Vanderbilt University human subjects institutional review board.</p><p>At least two weeks before the initial study, patients performed an incremental work test on a stationary cycle ergometer to determine <italic>V</italic><sc>o</sc><sub>2max</sub> and anaerobic threshold (AT). Airflow, O<sub>2</sub>, and CO<sub>2</sub> concentrations in inspired and expired air were measured by a computerized open-circuit indirect colorimetric cart (Parvo Medics, Kansas City, MO) with a mouthpiece and nose clip system. AT was determined by the V-slope method (<xref ref-type="bibr" rid="B25">25</xref>). AT determined by gas exchange corresponds to the onset of an increased lactate/pyruvate ratio in blood and indicates the level of exercise above which anaerobic mechanisms supplement aerobic energy production (<xref ref-type="bibr" rid="B25">25</xref>). At workloads below the AT, exercise can be continued for a prolonged period, whereas above the AT, fatigue will occur considerably faster (<xref ref-type="bibr" rid="B25">25</xref>). The experimental work rate was established by calculating 80% AT, which responded to 47 &#x000b1; 2% of the subject's <italic>V</italic><sc>o</sc><sub>2max</sub>. This workload was chosen because it is close enough to the AT to produce a physically challenging stress (i.e., large experimental signal) but is sustainable for a prolonged period of time. Subjects studied ranged from sedentary to regularly exercising, although not actively participating in competitive sports. Mean <italic>V</italic><sc>o</sc><sub>2max</sub> for the group was 34 &#x000b1; 2 ml &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (range 24&#x02013;51 ml &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>).</p><p>Type 1 diabetic subjects were studied during four separate 2-day studies. Day 1 consisted of morning and afternoon 2-h hyperinsulinemic-euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with cortisol infusion at 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort1) or 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort2). Day 2 was identical for all four protocols and consisted of 90-min euglycemic cycling exercise.</p><p>Patients were asked to avoid hypoglycemia during the 7 days preceding each visit. Patients checked blood glucose levels at least four times per day and reported values to the investigators before admission. Detection of any value &#x0003c;3.9 mmol/l resulted in rescheduling of the study. Patients were also asked to avoid exercise and consume a usual weight-maintaining diet for 3 days before each study. Each subject was admitted to the Vanderbilt Clinical Research Center on the afternoon before an experiment. Upon admission, patients were asked to discontinue usual insulin therapy, and two intravenous cannulas were inserted under 1% lidocaine local anesthesia. One cannula was placed in a retrograde fashion into a vein on the back of one hand. This hand was placed in a heated box (55&#x02013;60&#x000b0;C) so that arterialized blood could be obtained (<xref ref-type="bibr" rid="B26">26</xref>). The other cannula was placed in the contra lateral arm for infusion of dextrose, insulin, potassium chloride, hydrocortisone, and tritiated glucose during the study. Intravenous infusion of Humulin R (Eli Lilly, Indianapolis, IN) was started at a basal rate via a variable rate volumetric infusion pump (Imed, San Diego, CA). Patients then consumed a standardized dinner and 9:00 <sc>p.m.</sc> snack and were requested not to ingest any food after 10:00 <sc>p.m.</sc> The insulin infusion rate was increased during meal consumption. Throughout the night, glucose was measured every 30 min and the insulin infusion rate was adjusted to maintain blood glucose between 4.4&#x02013;6.7 mmol/l.</p><sec><title>Day 1 procedures.</title><p>The protocol consisted of an initial period (0&#x02013;120 min to simulate the isotope equilibration period of day 2), a morning hyperinsulinemic glucose clamp (120&#x02013;240 min), a rest period (240&#x02013;360 min), and an afternoon hyperinsulinemic glucose clamp (360&#x02013;480 min). At 120 min in all studies, a primed continuous infusion of insulin (9 pmol &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>) was started via a Medfusion 3010 pump (Medex-A Furon Healthcare Company, Deluth, GA). Potassium chloride (5 mmol/h) was also infused during each clamp period to reduce insulin-induced hypokalemia. Plasma glucose was measured every 5 min and maintained at the desired level via a variable rate infusion of 20% dextrose via an Imed pump (<xref ref-type="bibr" rid="B27">27</xref>). In anteEugly studies, plasma glucose was held constant at basal levels (&#x0223c;5 mmol/l). In anteHypo studies, plasma glucose was allowed to fall over a 30-min period to a target hypoglycemic plateau of &#x0223c;2.9 mmol/l. In anteCort studies, plasma glucose was held at euglycemia together with a constant 2-h intravenous physiologic infusion of cortisol of 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort1) or pharmacologic infusion at 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort2). Thus, in the two latter protocols, the effects of an increase of plasma cortisol, independent of hypoglycemia, on subsequent counterregulatory responses during exercise could be determinined. At 240 min, the insulin infusion was decreased to the basal rate; euglycemia was restored in anteHypo studies or maintained in anteEugly and anteCort studies. At 360 min, a second 2-h clamp identical to that in the morning was performed. At 480 min, the insulin infusion was decreased to the basal rate; euglycemia was again restored or maintained, and patients were allowed to consume a standardized meal. Evening and overnight procedures were then identical to those of admission night.</p></sec><sec><title>Day 2 procedures.</title><p>Day 2 procedures were identical for all four protocols. The experiments lasted 210 min and consisted of a tracer equilibration (0&#x02013;90 min), basal (90&#x02013;120 min), and exercise (120&#x02013;210 min). A primed (18 &#x003bc;Ci) continuous infusion (0.8 &#x003bc;Ci/min) of high-performance liquid chromatography&#x02013;purified [3-<sup>3</sup>H] glucose (Perkin Elmer Life Sciences, Boston, MA; 11.5 mCi &#x000b7; mmol<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup>) was started at 0 min and continued throughout the study to measure glucose kinetics. Exercise consisted of 90 min continuous cycling (at 60&#x02013;70 rpm) on an upright cycle ergometer (Medical Graphics, Yorba Linda, LA) at 80% of the individual's AT (&#x0223c;50% <italic>V</italic><sc>o</sc><sub>2max</sub>). During exercise, the basal insulin infusion rate was adjusted down or maintained at 1 unit/h. This rate of insulin infusion has been shown to reproduce basal levels of insulin (60 &#x000b1; 6 pmol/l) throughout the 90-min cycling exercise (<xref ref-type="bibr" rid="B3">3</xref>). Plasma glucose was measured every 5 min and maintained at basal levels (&#x0223c;5 mmol/l) throughout the study via a variable rate infusion of 20% dextrose. After completion of the exercise protocol, patients consumed a meal and were discharged.</p></sec><sec><title>Tracer methodology.</title><p>Rates of glucose appearance, endogenous glucose production (EGP), and glucose utilization were calculated according to the method of Wall et al. (<xref ref-type="bibr" rid="B28">28</xref>). EGP was calculated by determining the total rate of glucose appearance (which comprises both EGP and any exogenous glucose infused to maintain euglycemia) and subtracting from it the amount of exogenous glucose infused. It is now recognized that this approach is not fully quantitative because underestimates of total rate of glucose appearance and rates of glucose disposal can be obtained. This underestimate can be largely overcome by use of a highly purified tracer and taking measurements under steady-state conditions (i.e., constant glucose-specific activity). To minimize changes in specific activity, the tracer infusion rate was gradually doubled during the first 30 min of exercise. During the last 60 min of exercise, proportional additional increases of tracer delivery were made commensurate with changes of the exogenous glucose infusion rate.</p></sec><sec><title>Analytical methods.</title><p>Plasma glucose concentrations were measured in triplicate using the glucose oxidase method with a glucose analyzer (Beckman, Fullerton, CA). Blood for hormones and intermediary metabolites was drawn twice during the basal period and every 15&#x02013;30 min during the clamp period. Glucagon was measured according to the method of Aguilar-Parada, Eisentraut, and Unger (<xref ref-type="bibr" rid="B29">29</xref>) with an interassay coefficient of variation (CV) of 15% free. Insulin was measured after polyethelene glycol extraction as previously described (<xref ref-type="bibr" rid="B30">30</xref>) with an interassay CV of 11%. Catecholamines were determined by high-pressure liquid chromatography (<xref ref-type="bibr" rid="B31">31</xref>) with an interassay CV of 12% for both epinephrine and norepinephrine. We made two modifications to the procedure for catecholamine determination: <italic>1</italic>) we used a five-point rather than one-point standard calibration curve; <italic>2</italic>) we spiked the initial and final samples of plasma with known amounts of epinephrine and norepinephrine so that accurate identification of the relevant catecholamine peaks could be made. Cortisol was assayed using the Clinical Assays Gamma Coat Radioimmunoassay (RIA) kit with an interassay CV of 6%. Growth hormone was determinined by RIA (<xref ref-type="bibr" rid="B32">32</xref>) with an interassay CV of 8%. Pancreatic polypeptide was measured by RIA using the method of Hagopian et al. (<xref ref-type="bibr" rid="B33">33</xref>) with an interassay CV of 8%. Lactate, glycerol, alanine, and &#x003b2;-hydroxybutyrate were measured on deproteinized whole blood using the method of Lloyd et al. (<xref ref-type="bibr" rid="B34">34</xref>). Nonesterified fatty acids (NEFAs) were measured using the WAKO kit adopted for use on a centrifugal analyzer (<xref ref-type="bibr" rid="B35">35</xref>). Cardiovascular parameters (heart rate and systolic and diastolic blood pressure) were measured every 10 min during clamp studies. Hypoglycemic symptoms were quantified using a previously validated semiquantitative questionnaire (<xref ref-type="bibr" rid="B36">36</xref>). Each individual was asked to rate his/her experience of the symptoms twice during the control period and every 15 min during experimental periods. Symptoms measured included sweaty, tremor/shaky, hot, thirsty/dry mouth, agitation/irritability, palpitations, tired/fatigued, confusion/dizzy/difficulty thinking, blurriness of vision, and sleepy. The ratings of the first six symptoms were summed to get the autonomic score, whereas the ratings from the last six symptoms provide a neuroglycopenic symptom score.</p></sec><sec><title>Statistical analysis.</title><p>Data are expressed as means &#x000b1; SE and were analyzed using parametric two-way analysis of variance with repeated measures. Tukey's post hoc analysis or Student's <italic>t</italic> tests were used to delineate statistical significance across time within each group and for anteHypo or anteCort group compared with the anteEugly control group. A <italic>P</italic> value of &#x0003c;0.05 was accepted as statistically significant. The baseline and final 30 min of exercise on day 2 were compared for most parameters. Baseline data represent an average of two time points (110 and 120 min), and the final 30-min data represent an average of three measures taken during this time (180, 195, and 210 min).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Day 1</title><sec><title>Plasma glucose, insulin, cortisol levels, epinephrine, and symptom responses.</title><p>Basal plasma glucose levels were similar among the four experimental groups (<xref ref-type="table" rid="T1">Table 1</xref>). During the final 30 min of clamp studies, plasma glucose levels were similar between anteEugly, anteCort1, and anteCort2. Plasma insulin levels were also similar among the four experimental groups during basal periods and during the final 30 min of clamp studies (<xref ref-type="table" rid="T1">Table 1</xref>). Morning basal cortisol levels were similar among the four experimental groups (<xref ref-type="table" rid="T1">Table 1</xref>). During antecedent hypoglycemia and low-dose cortisol infusion (anteCort1), there were equivalent increases in day 1 morning and afternoon plasma cortisol levels. High-dose cortisol (anteCort2) resulted in approximately twofold greater levels of the hormone during the final 30 min of morning and afternoon clamps compared with anteHypo and anteCort1. During anteHypo, plasma epinephrine increased from basal levels of 148 &#x000b1; 37 to 2,718 &#x000b1; 427 pmol/l and symptoms increased from 17 &#x000b1; 3 to 54 &#x000b1; 18.</p><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>Plasma glucose, insulin, and cortisol levels during two 2-h hyperinsulinemic-euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions of 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort1) or 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort2) on day 1</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" colspan="1"/><th align="center" colspan="2" rowspan="1">Morning clamp<hr/></th><th align="center" colspan="2" rowspan="1">Afternoon clamp<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Basal</th><th align="center" rowspan="1" colspan="1">Final 30 min of exercise</th><th align="center" rowspan="1" colspan="1">Basal</th><th align="center" rowspan="1" colspan="1">Final 30 min of exercise</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Plasma glucose (mmol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.4 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.0 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.3 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.2 &#x000b1; 0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.3 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.9 &#x000b1; 0.1<xref ref-type="table-fn" rid="TF1-1">*</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.2 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.9 &#x000b1; 0.1<xref ref-type="table-fn" rid="TF1-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.4 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.0 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.5 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.1 &#x000b1; 0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.4 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.1 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.5 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.2 &#x000b1; 0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma insulin (pmol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">94 &#x000b1; 15</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">588 &#x000b1; 33</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">60 &#x000b1; 12</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">588 &#x000b1; 42</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">90 &#x000b1; 15</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">576 &#x000b1; 36</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">58 &#x000b1; 9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">606 &#x000b1; 39</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">108 &#x000b1; 17</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">606 &#x000b1; 77</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">93 &#x000b1; 19</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">588 &#x000b1; 72</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">93 &#x000b1; 15</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">582 &#x000b1; 41</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">66 &#x000b1; 15</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">602 &#x000b1; 47</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma Cortisol (nmol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">419 &#x000b1; 69</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">328 &#x000b1; 48</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">290 &#x000b1; 46</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">301 &#x000b1; 35</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">374 &#x000b1; 47</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">696 &#x000b1; 96<xref ref-type="table-fn" rid="TF1-1">*</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">351 &#x000b1; 46</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">702 &#x000b1; 98<xref ref-type="table-fn" rid="TF1-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">341 &#x000b1; 39</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">720 &#x000b1; 39<xref ref-type="table-fn" rid="TF1-1">*</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">343 &#x000b1; 39</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">703 &#x000b1; 41<xref ref-type="table-fn" rid="TF1-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">469 &#x000b1; 55</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,202 &#x000b1; 70<xref ref-type="table-fn" rid="TF1-1">*</xref><xref ref-type="table-fn" rid="TF1-2">&#x02020;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">579 &#x000b1; 60<xref ref-type="table-fn" rid="TF1-1">*</xref><xref ref-type="table-fn" rid="TF1-2">&#x02020;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,216 &#x000b1; 70<xref ref-type="table-fn" rid="TF1-1">*</xref><xref ref-type="table-fn" rid="TF1-2">&#x02020;</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Data are means &#x000b1; SEM. <italic>n</italic> = 22 patients (11 men/11 women) with type 1 diabetes.</p></fn><fn id="TF1-1"><p>*Significant difference versus anteEugly.</p></fn><fn id="TF1-2"><p>&#x02020;Significant difference versus anteHypo and anteCort1 (<italic>P</italic> &#x0003c; 0.05).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>Day 2</title><sec><title>Glucose, insulin, and counterregulatory hormone levels.</title><p>Basal plasma glucose levels were similar among the four experimental groups (anteEugly [5.2 &#x000b1; 0.1 mmol/l], anteHypo [5.2 &#x000b1; 0.1 mmol/l], anteCort1 [5.5 &#x000b1; 0.1 mmol/l], and anteCort2 [5.4 &#x000b1; 0.1 mmol/l]) and were maintained equivalently throughout exercise (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><fig id="F1" position="float"><label>FIG. 1.</label><caption><p>Plasma glucose (<italic>A</italic>) and insulin (<italic>B</italic>) concentrations (means &#x000b1; SE) during day 2 euglycemic exercise studies in 22 patients (11 men/11 women) with type 1 diabetes. On the previous day, patients had undergone two 120-min euglycemic clamps (&#x025cf;, anteEugly), hypoglycemic clamps (&#x025a0;, anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (&#x025b2;, anteCort1) or 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (&#x025bc;, anteCort2) on day 1. Plasma glucose and insulin levels were comparable among the four experimental groups during basal and exercise periods.</p></caption><graphic xlink:href="zdb0090958320001"/></fig><p>Basal plasma insulin levels were similar among the four experimental groups (anteEugly [98 &#x000b1; 16 pmol/l], anteHypo [102 &#x000b1; 16 pmol/l], anteCort1 [108 &#x000b1; 22 pmol/l], and anteCort2 [107 &#x000b1; 14 pmol/l]). During exercise, plasma insulin levels were allowed to fall similarly in a physiologic manner among the four groups (anteEugly [82 &#x000b1; 11 pmol/l], anteHypo [84 &#x000b1; 11 pmol/l], anteCort1 [90 &#x000b1; 23 pmol/l], and anteCort2 [89 &#x000b1; 10 pmol/l]; <xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><p>Basal values of glucagon, growth hormone, and cortisol were similar at the start of each protocol (<xref ref-type="table" rid="T2">Table 2</xref>). Incremental increases of glucagon were reduced during the final 30 min of exercise in anteHypo (4 &#x000b1; 2 ng/l), anteCort1 (1 &#x000b1; 3 ng/l), and anteCort2 (2 &#x000b1; 1 ng/l) compared with anteEugly (9 &#x000b1; 2 ng/l; <italic>P</italic> &#x0003c; 0.05; <xref ref-type="fig" rid="F2">Fig. 2</xref>). Incremental increases of growth hormone were also reduced during the final 30 min of exercise in anteHypo (3 &#x000b1; 1 &#x003bc;g/l), anteCort1 (4 &#x000b1; 1 &#x003bc;g/l), and anteCort2 (4 &#x000b1; 2 &#x003bc;g/l) compared with anteEugly (9 &#x000b1; 2 &#x003bc;g/l; <italic>P</italic> &#x0003c; 0.05; <xref ref-type="fig" rid="F3">Fig. 3</xref>). Exercise-induced increments in cortisol were less (<italic>P</italic> &#x0003c; 0.05) in anteHypo (74 &#x000b1; 44 nmol/l), anteCort1 (35 &#x000b1; 20 nmol/l), and anteCort2 (73 &#x000b1; 52 nmol/l) compared with anteEugly (204 &#x000b1; 63 nmol/l) (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>Basal value for counterregulatory hormones at the start of day 2 exercise after two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions of 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort) or 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort2) on day 1</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">anteEugly</th><th align="center" rowspan="1" colspan="1">anteHypo</th><th align="center" rowspan="1" colspan="1">anteCort1</th><th align="center" rowspan="1" colspan="1">anteCort2</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Epinephrine (pmol/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">279 &#x000b1; 55</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">225 &#x000b1; 38</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">290 &#x000b1; 55</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">230 &#x000b1; 33</td></tr><tr><td align="left" rowspan="1" colspan="1">Norepinephrine (nmol/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.6 &#x000b1; 0.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.4 &#x000b1; 0.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.3 &#x000b1; 0.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.2 &#x000b1; 0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Pancreatic polypeptide (pmol/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">16 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">19 &#x000b1; 6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">21 &#x000b1; 6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">20 &#x000b1; 4</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucagon (ng/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">44 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">45 &#x000b1; 4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">54 &#x000b1; 10</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">43 &#x000b1; 3</td></tr><tr><td align="left" rowspan="1" colspan="1">Growth hormone (&#x003bc;g/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4 &#x000b1; 2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2 &#x000b1; 1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2 &#x000b1; 1</td></tr><tr><td align="left" rowspan="1" colspan="1">Cortisol (nmol/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">359 &#x000b1; 55</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">367 &#x000b1; 47</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">286 &#x000b1; 62</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">442 &#x000b1; 59</td></tr></tbody></table><table-wrap-foot><fn><p>Data are means &#x000b1; SEM. <italic>n</italic> = 22 type 1 diabetic subjects (11 men/11 women).</p></fn></table-wrap-foot></table-wrap><fig id="F2" position="float"><label>FIG. 2.</label><caption><p>Average plasma glucagon (<italic>A</italic>), growth hormone (<italic>B</italic>), pancreatic polypeptide (<italic>C</italic>), and cortisol (<italic>D</italic>) levels (means &#x000b1; SE) during the final 30 min of day 2 exercise in 22 type 1 diabetic patients (11 men/11 women). On the previous day, patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort1) or 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort2) on day 1. There were significantly fewer increments of glucagon, growth hormone, and pancreatic polypeptide during the final 30 min of exercise from basal levels in anteHypo and anteCort compared with anteEugly. *<italic>P</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="zdb0090958320002"/></fig><fig id="F3" position="float"><label>FIG. 3.</label><caption><p>Plasma epinephrine (<italic>A</italic>) and norepinephrine (<italic>B</italic>) levels (means &#x000b1; SE) during the final 30 min of day 2 exercise in 22 type 1 diabetic patients (11 men/11 women). On the previous day, patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort1) or 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort2) on day 1. There were significantly fewer increases of epinephrine and norepinephrine during the final 30 min of exercise from basal levels in anteHypo and anteCort compared with anteEugly. *<italic>P</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="zdb0090958320003"/></fig><p>Basal values of epinephrine, norepinephrine, and pancreatic polypeptide were similar at the start of each protocol (<xref ref-type="table" rid="T2">Table 2</xref>). ANS responses during exercise were also reduced by day 1 antecedent hypoglycemia and cortisol infusions. Incremental increases of epinephrine were reduced during the final 30 min of exercise in anteHypo (316 &#x000b1; 60 pmol/l), anteCort1 (212 &#x000b1; 31 pmol/l), and anteCort2 (354 &#x000b1; 66 pmol/l) compared with anteEugly (582 &#x000b1; 101 pmol/l; <italic>P</italic> &#x0003c; 0.05; <xref ref-type="fig" rid="F3">Fig. 3</xref>). Exercise-induced increments of norepinephrine were also less in anteHypo (2.2 &#x000b1; 0.4 nmol/l), anteCort1 (2.0 &#x000b1; 0.2 nmol/l), and anteCort2 (2.0 &#x000b1; 0.3 nmol/l) compared with anteEugly (4.0 &#x000b1; 0.5 nmol/l; <italic>P</italic> &#x0003c; 0.05; <xref ref-type="fig" rid="F3">Fig. 3</xref>). Incremental increases of pancreatic polypeptide from baseline were also blunted during the final 30 min of exercise in anteHypo (7.4 &#x000b1; 2 pg/l), anteCort1 (4.0 &#x000b1; 1.4 pg/l), and anteCort2 (7.5 &#x000b1; 2 pg/l) compared with anteEugly (17 &#x000b1; 5 pg/l; <italic>P</italic> &#x0003c; 0.05; <xref ref-type="fig" rid="F2">Fig. 2</xref>).</p></sec><sec><title>Glucose kinetics.</title><p>During the final 30 min of exercise, the exogenous glucose infusion rates used to maintain euglycemia were significantly higher in anteHypo (19 &#x000b1; 2 &#x003bc;mol &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>), anteCort1 (20 &#x000b1; 4 &#x003bc;mol &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>), and anteCort2 (19 &#x000b1; 3 &#x003bc;mol &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>) compared with anteEugly (11 &#x000b1; 2 &#x003bc;mol &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>; <italic>P</italic> &#x0003c; 0.05; <xref ref-type="fig" rid="F4">Fig. 4</xref>). EGP was significantly lower in anteCort1 (11 &#x000b1; 2 &#x003bc;mol &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>) and anteCort2 (14 &#x000b1; 2 &#x003bc;mol &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>) compared with anteEugly (22 &#x000b1; 3 &#x003bc;mol &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>; <italic>P</italic> &#x0003c; 0.05; <xref ref-type="fig" rid="F4">Fig. 4</xref>).</p><fig id="F4" position="float"><label>FIG. 4.</label><caption><p>Glucose kinetics (means &#x000b1; SE) during the final 30 min of day 2 exercises in 22 type 1 diabetic patients (11 men/11 women). <italic>A</italic>: Glucose infusion rate. <italic>B</italic>: Glucose utilization. <italic>C</italic>: EGP. On the previous day, patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps, or euglycemic clamps with intravenous cortisol infusions at 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort1) or 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort2) on day 1. *<italic>P</italic> &#x0003c; 0.05 versus anteEugly.</p></caption><graphic xlink:href="zdb0090958320004"/></fig></sec><sec><title>Intermediary metabolism.</title><p>Basal levels of lactate, alanine, &#x003b2;-hydroxybutyrate glycerol, and NEFA levels were similar and are shown in <xref ref-type="table" rid="T3">Table 3</xref>. There were significantly different responses of intermediary metabolites during day 2 exercise. Following day 1 hypoglycemia, anteCort1, and anteCort2, glyerol and NEFA responses during exercise were reduced compared with anteEugly (<italic>P</italic> &#x0003c; 0.05). Plasma lactate responses were also reduced during exercise following day 1 anteHypo and anteCort1 (<italic>P</italic> &#x0003c; 0.05). &#x003b2;-Hydroxybutyrate levels did not significantly increase during exercise following anteHypo and anteCort1 and fell following anteCort2 (<xref ref-type="table" rid="T3">Table 3</xref>).</p><table-wrap id="T3" position="float"><label>TABLE 3</label><caption><p>Blood lactate, alanine, &#x003b2;-hydroxybutyrate, NEFA, and glycerol levels during day 2 exercise euglycemic clamp studies after two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions of 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort1) or 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort2) on day 1</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Basal period</th><th align="center" rowspan="1" colspan="1">Final 30 min of exercise</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Lactate (mmol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.8 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.9 &#x000b1; 0.2<xref ref-type="table-fn" rid="TF3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.8 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.3 &#x000b1; 0.1<xref ref-type="table-fn" rid="TF3-1">*</xref><xref ref-type="table-fn" rid="TF3-2">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.7 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.1 &#x000b1; 0.2<xref ref-type="table-fn" rid="TF3-1">*</xref><xref ref-type="table-fn" rid="TF3-2">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.9 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.9 &#x000b1; 0.1<xref ref-type="table-fn" rid="TF3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Alanine (&#x003bc;mol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">329 &#x000b1; 34</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">418 &#x000b1; 43<xref ref-type="table-fn" rid="TF3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">330 &#x000b1; 32</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">367 &#x000b1; 30<xref ref-type="table-fn" rid="TF3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">310 &#x000b1; 60</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">360 &#x000b1; 40<xref ref-type="table-fn" rid="TF3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">378 &#x000b1; 32</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">419 &#x000b1; 29<xref ref-type="table-fn" rid="TF3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003b2;-hydroxybutyrate (&#x003bc;mol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">40 &#x000b1; 10</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">61 &#x000b1; 10<xref ref-type="table-fn" rid="TF3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">48 &#x000b1; 13</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">66 &#x000b1; 18</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">37 &#x000b1; 5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">51 &#x000b1; 10</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">50 &#x000b1; 10</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">40 &#x000b1; 10<xref ref-type="table-fn" rid="TF3-2">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">NEFA (&#x003bc;mol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">143 &#x000b1; 25</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">383 &#x000b1; 72<xref ref-type="table-fn" rid="TF3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">227 &#x000b1; 42<xref ref-type="table-fn" rid="TF3-3">&#x02021;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">298 &#x000b1; 48<xref ref-type="table-fn" rid="TF3-2">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">148 &#x000b1; 21</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">219 &#x000b1; 61<xref ref-type="table-fn" rid="TF3-2">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">149 &#x000b1; 28</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">199 &#x000b1; 39<xref ref-type="table-fn" rid="TF3-2">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Glycerol (&#x003bc;mol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">44 &#x000b1; 9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">145 &#x000b1; 18<xref ref-type="table-fn" rid="TF3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">48 &#x000b1; 10</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">111 &#x000b1; 16<xref ref-type="table-fn" rid="TF3-1">*</xref><xref ref-type="table-fn" rid="TF3-2">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">77 &#x000b1; 20</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">111 &#x000b1; 21<xref ref-type="table-fn" rid="TF3-1">*</xref><xref ref-type="table-fn" rid="TF3-2">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">50 &#x000b1; 13</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">100 &#x000b1; 14<xref ref-type="table-fn" rid="TF3-1">*</xref><xref ref-type="table-fn" rid="TF3-2">&#x02020;</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Data are means &#x000b1; SEM. <italic>n</italic> = 22 type 1 diabetic subjects (11 men/11 women).</p></fn><fn id="TF3-1"><p>*Significant difference versus basal level (<italic>P</italic> &#x0003c; 0.05).</p></fn><fn id="TF3-2"><p>&#x02020;Significantly reduced versus anteEugly (<italic>P</italic> &#x0003c; 0.05).</p></fn><fn id="TF3-3"><p>&#x02021;Significantly increased compared with other groups (<italic>P</italic> &#x0003c; 0.05).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>Cardiovascular parameters.</title><p>Heart rate and systolic and diastolic blood pressure were similar at baseline and changed similarly during exercise in all four groups (<xref ref-type="table" rid="T4">Table 4</xref>).</p><table-wrap id="T4" position="float"><label>TABLE 4</label><caption><p>Cardiovascular responses during day 2 exercise euglycemic clamp studies after patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions of 1 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort1) or 2 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup> (anteCort2) on day 1</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Basal period</th><th align="center" rowspan="1" colspan="1">Final 30 min of exercise</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Heart rate (bpm)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">70 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">136 &#x000b1; 4<xref ref-type="table-fn" rid="TF4-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">70 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">132 &#x000b1; 3<xref ref-type="table-fn" rid="TF4-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">71 &#x000b1; 2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">131 &#x000b1; 4<xref ref-type="table-fn" rid="TF4-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">69 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">135 &#x000b1; 3<xref ref-type="table-fn" rid="TF4-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">113 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">134 &#x000b1; 4<xref ref-type="table-fn" rid="TF4-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">115 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">136 &#x000b1; 5<xref ref-type="table-fn" rid="TF4-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">114 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">141 &#x000b1; 5<xref ref-type="table-fn" rid="TF4-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">111 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">134 &#x000b1; 4<xref ref-type="table-fn" rid="TF4-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">70 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">69 &#x000b1; 5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">69 &#x000b1; 2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">68 &#x000b1; 2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">69 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">75 &#x000b1; 4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">69 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">65 &#x000b1; 2</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean blood pressure (mmHg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteEugly</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">86 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">89 &#x000b1; 2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteHypo</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">86 &#x000b1; 2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">91 &#x000b1; 2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">86 &#x000b1; 7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">85 &#x000b1; 2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;anteCort2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">83 &#x000b1; 2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">87 &#x000b1; 2</td></tr></tbody></table><table-wrap-foot><fn><p>Data are means &#x000b1; SEM. <italic>n</italic> = 22 type 1 diabetic subjects (11 men/11 women).</p></fn><fn id="TF4-1"><p>*Significant difference versus basal level (<italic>P</italic> &#x0003c; 0.05).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This study has investigated the mechanism(s) responsible for exercise-associated counterregulatory failure in those with type 1 diabetes. Our results demonstrate that antecedent physiologic and pharmacologic levels of plasma cortisol similar to prior hypoglycemia result in widespread blunting of neuroendocrine, ANS, and metabolic responses during next-day moderate-intensity exercise in subjects with type 1 diabetes.</p><p>Exercise-associated hypoglycemia is a significant clinical problem in patients with type 1 diabetes. In fact, recent work has reported that patients will overcompensate following episodes of hypoglycemia by excessively decreasing insulin and subsequently compromising glycemic control with increases in A1C. These actions then lead to paradoxical deterioration of glycemic control rather than the expected improvements in A1C following exercise (<xref ref-type="bibr" rid="B37">37</xref>). We and others have demonstrated that antecedent hypoglycemia and exercise can establish reciprocal feed-forward vicious cycles that cause downregulation of ANS and neuroendocrine counterregulatory response during each subsequent stress (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B39">39</xref>). However, the specific mechanisms responsible for the failure of these physiologic counterregulatory mechanisms are not known. Thus, this study was conducted with the aim of providing knowledge regarding the mechanisms responsible for the inability of type 1 diabetic individuals to defend plasma glucose during exercise following antecedent hypoglycemia.</p><p>Glucose levels were carefully controlled at all times during the 2-day studies. Hypoglycemia was avoided during the overnight stays in our clinical research center so that the effects of antecedent cortisol on subsequent exercise could be clearly determined. Additionally, plasma glucose levels were clamped equivalently during all four protocols. This is important because during exercise hyperglycemia reduces, whereas even minimal reductions in plasma glucose can amplify, some neuroendocrine responses (<xref ref-type="bibr" rid="B40">40</xref>). Insulin levels were also carefully controlled during the clamp studies. During exercise the insulin levels were equated and were reduced to simulate the usual physiologic fall that occurs in nondiabetic individuals. The tight regulation of insulin is an important element of our experimental design because it allows determination of the effects of the antecedent corticosteroid on subsequent exercise in the presence of low (and reducing) levels of insulin. Secondly, the inability to suppress insulin levels during exercise in those with type 1 diabetes is recognized as an important causative factor for exercise-induced hypoglycemia (<xref ref-type="bibr" rid="B41">41</xref>).</p><p>There are numerous reports of prior increases of corticosteroids blunting subsequent physiologic responses to a wide variety of differing physiologic stress (<xref ref-type="bibr" rid="B7">7</xref><xref ref-type="bibr" rid="B8"/><xref ref-type="bibr" rid="B9"/><xref ref-type="bibr" rid="B10"/><xref ref-type="bibr" rid="B11"/><xref ref-type="bibr" rid="B12"/><xref ref-type="bibr" rid="B13"/><xref ref-type="bibr" rid="B14"/><xref ref-type="bibr" rid="B15"/><xref ref-type="bibr" rid="B16"/><xref ref-type="bibr" rid="B17"/><xref ref-type="bibr" rid="B18"/><xref ref-type="bibr" rid="B19"/><xref ref-type="bibr" rid="B20"/>&#x02013;<xref ref-type="bibr" rid="B21">21</xref>). It is unknown whether prior increases of corticosteroids can blunt subsequent homeostatic/counterregulatory responses to exercise. In this present study, we clearly demonstrate that antecedent increases of both physiologic (by matching the increase of cortisol occurring during prior hypoglycemia) and pharmacologic levels of cortisol can substantially reduce counterregulatory response during next-day submaximal exercise.</p><p>In subjects with type 1 diabetes, glucagon responses to hypoglycemia are gradually lost over the first few years following diagnosis. However, glucagon release during exercise is preserved, indicating that the pancreatic &#x003b1;-cell deficit is stimulus specific. After antecedent euglycemia, our patients were able to mount a glucagon response similar to that previously observed in nondiabetic subjects during exercise of similar duration and intensity (<xref ref-type="bibr" rid="B4">4</xref>). Day 1 hypoglycemia significantly reduced the glucagon response to subsequent exercise. Both prior physiologic (anteCort1) and pharmacologic (anteCort2) cortisol elevation without hypoglycemia also resulted in similar glucagon-blunting effects. The regulation of glucagon release during exercise is controversial. There are data both for and against ANS regulation of the hormone during exercise (<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B43">43</xref>). However, of the studies reporting positive modulation of glucagon release by ANS during exercise, there is debate whether regulation occurs via sympathetic or parasympathetic nervous system mechanisms (<xref ref-type="bibr" rid="B42">42</xref>). In this present study, prior physiologic and pharmacologic increases of cortisol had similar effects to downregulate branches of ANS activity during exercise. Epinephrine (adrenomedullary), norepinephrine (sympathetic neural), and pancreatic polypeptide (also &#x003b2;-adrenoreceptor sympathetic nervous system mediated during exercise [<xref ref-type="bibr" rid="B44">44</xref>]) were all blunted by antecedent low- and high-dose cortisol. Additionally, a direct effect of epinephrine on glucagon release has also been proposed. Thus, absent an effect of cortisol to directly inhibit glucagon release from pancreatic &#x003b1;-cells, it would appear that the blunted response of the hormone following low- and high-dose cortisol infusions was due to reduced direct ANS activation and/or via blunted epinephrine levels.</p><p>The current study also demonstrated that growth hormone responses to exercise were blunted after either prior hypoglycemia or both physiologic and pharmacologic antecedent cortisol elevations. The central pathways responsible for hypoglycemia and corticosteroid downregulation of neuroendocrine responses during subsequent exercise are not known. Much recent work has demonstrated the importance of AMP-activated protein kinase (AMPK) as a key regulator of carbohydrate and lipid metabolism during exercise (<xref ref-type="bibr" rid="B45">45</xref>). Of note are recent studies in rats demonstrating that hypothalamic AMPK can also regulate neuroendocrine responses during hypoglycemia (<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B47">47</xref>). The study of Kola et al. (<xref ref-type="bibr" rid="B48">48</xref>) of humans with Cushing's syndrome has determined that AMPK activity in visceral adipose tissue is reduced by 70%, thus providing an intriguing possibility that acute increases in corticosteroids may also have an effect to downregulate brain AMPK activity. Recent work has also demonstrated the action of central N-methyl-D-aspartate to stimulate secretion of epinephrine and norepinephrine (<xref ref-type="bibr" rid="B49">49</xref>). Liu et al. (<xref ref-type="bibr" rid="B50">50</xref>) have reported that corticosterone can rapidly inhibit N-methyl-D-aspartate receptor activity in cultured hippocampal neurons, thus providing another possible or complimentary central molecular target for corticosteroid downregulation of neuroendocrine and ANS activity during subsequent exercise.</p><p>The decreased ANS and neuroendocrine responses following day 1 physiologic and pharmacologic cortisol administration had profound effects on reducing metabolic responses during day 2 exercise. During exercise, plasma glucose levels are maintained when EGP matches the requirements of the working muscles. Following antecedent physiologic and pharmacologic elevations of cortisol, the key metabolic mechanism of EGP was reduced during day 2 exercise. Glucose infusion rates were also increased during exercise following both doses of day 1 cortisol and antecedent hypoglycemia. The increased glucose infusion rates represent an aggregate reduction in counterregulatory responses because more glucose was required to maintain euglycemia during exercise. Other metabolic counterregulatory responses were also similarly reduced following low- and high-dose cortisol and antecedent hypoglycemia. Plasma lactate, a marker of glycogenolysis and an important substrate for gluconeogenesis, was reduced following both antecedent infusions of cortisol, presumably due to the blunted sympathetic nervous system responses. Similarly, plasma glycerol and blood NEFA responses, indicators of lipolysis, were also blunted by the reduced sympathetic nervous system and growth hormone response. Lipolysis is a key metabolic counterregulatory mechanism during exercise. Glycerol is an important gluconeogenic substrate, and NEFA provides energy for the working muscle and hepatic gluconeogenesis and also inhibits insulin's ability to suppress hepatic glycogenolysis (<xref ref-type="bibr" rid="B19">19</xref>).</p><p>Current clinical practice stresses the importance of physical activity in diabetes management. Exercise improves insulin sensitivity, helps in weight maintenance, and lowers the risk of cardiovascular disease. Consequently, growing numbers of those with type 1 diabetes participate in different forms of exercise such as soccer, tennis matches, outdoor hiking, or bike rides with intensity and duration similar to our exercise model. The present study, as well as our previous study (<xref ref-type="bibr" rid="B3">3</xref>), has shown that prior hypoglycemia in type 1 diabetes can blunt counterregulatory responses to subsequent exercise, thereby increasing the risk for future hypoglycemia. This present study provides evidence, for the first time, that antecedent physiologic and pharmacologic levels of corticosteroids on a background of hyperinsulinemic euglycemia can produce substantial reductions in counterregulatory responses (similar to prior hypoglycemia) during subsequent exercise in type 1 diabetes.</p><p>In summary, this study demonstrated, despite equivalent glucose, insulin, and relative workloads, that antecedent hypoglycemia, physiologic (anteCort1), and supraphysiologic (anteCort2) levels of cortisol blunted neuroendocrine (growth hormone and glucagon), ANS (epinephrine, norepinephrine, and pancreatic polypeptide), and metabolic (glucose kinetics, lipolysis, and glycogenolysis) counterregulatory responses during subsequent exercise in individuals with type 1 diabetes. We conclude that both prior physiologic and pharmacologic increases in cortisol can blunt a wide spectrum of homeostatic responses during subsequent exercise and may play a role in the development of exercise-related counterregulatory failure in those with type 1 diabetes.</p></sec></body><back><fn-group><fn fn-type="other"><p>Clinical trial reg. no. NCT00742521, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p></fn><fn fn-type="financial-disclosure"><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;advertisement&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn><fn fn-type="other"><p><bold>See accompanying commentary, p. <related-article related-article-type="commentary" vol="58" page="1951" id="d32e1637" ext-link-type="pmc">1951</related-article>.</bold></p></fn></fn-group><ack><title>Acknowledgments</title><p>This work was supported by research grants from the National Institutes of Health (HL056693 and DK069803), Diabetes Research and Training Grant (DK20593), and General Clinical Research Center Grant (RR00095).</p><p>No potential conflicts of interest relevant to this article were reported.</p><p>Parts of this study were presented in abstract form at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 5&#x02013;9 June 2009.</p><p>We thank Eric Allen, Angelina Penaloza, Wanda Snead, Damon Maes, Antoinette Richardson, Anthony Neill, Ginger Barnett, Bin Gong, Nathan Jones, and Shampa Nasreen for expert technical assistance. We are grateful for the exceptional care and support provided by the nursing staff of the Vanderbilt General Clinical Research Center. We thank Jan Hicks for her expert assistance in preparation of this manuscript.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><collab>Diabetes Control and Complications Trial Research Group.</collab><article-title>The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus</article-title>.
<source>N Engl J Med</source><year>1993</year>;
<volume>329</volume>:
<fpage>977</fpage>&#x02013;
<lpage>986</lpage><pub-id pub-id-type="pmid">8366922</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><collab>The Diabetes Control and Complications Trial Research Group</collab>
<article-title>Hypoglycemia in the Diabetes Control and Complications Trial</article-title>.
<source>Diabetes</source><year>1997</year>;
<volume>46</volume>:
<fpage>271</fpage>&#x02013;
<lpage>286</lpage><pub-id pub-id-type="pmid">9000705</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galassetti</surname><given-names>P</given-names></name><name><surname>Tate</surname><given-names>D</given-names></name><name><surname>Neill</surname><given-names>RA</given-names></name><name><surname>Morrey</surname><given-names>S</given-names></name><name><surname>Wassermann</surname><given-names>DH</given-names></name><name><surname>Davis</surname><given-names>SN</given-names></name></person-group>:
<article-title>Effect of antecedent hypoglycemia on counterregulatory responses to subsequent euglycemic exercise in type 1 diabetes</article-title>.
<source>Diabetes</source><year>2003</year>;
<volume>52</volume>:
<fpage>1761</fpage>&#x02013;
<lpage>1769</lpage><pub-id pub-id-type="pmid">12829644</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>SN</given-names></name><name><surname>Galassetti</surname><given-names>P</given-names></name><name><surname>Wassermann</surname><given-names>DH</given-names></name><name><surname>Tate</surname><given-names>D</given-names></name></person-group>:
<article-title>Effects of antecedent hypoglycemia on subsequent counterregulatory responses to exercise</article-title>.
<source>Diabetes</source><year>2000</year>;
<volume>49</volume>:
<fpage>73</fpage>&#x02013;
<lpage>81</lpage><pub-id pub-id-type="pmid">10615952</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoval</surname><given-names>DA</given-names></name><name><surname>Guy</surname><given-names>DLA</given-names></name><name><surname>Richardson</surname><given-names>MA</given-names></name><name><surname>Ertl</surname><given-names>AC</given-names></name><name><surname>Davis</surname><given-names>SN</given-names></name></person-group>:
<article-title>Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes</article-title>.
<source>Diabetes</source><year>2004</year>;
<volume>53</volume>:
<fpage>1798</fpage>&#x02013;
<lpage>1806</lpage><pub-id pub-id-type="pmid">15220204</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galassetti</surname><given-names>P</given-names></name><name><surname>Mann</surname><given-names>S</given-names></name><name><surname>Tate</surname><given-names>D</given-names></name><name><surname>Neill</surname><given-names>RA</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name><name><surname>Wassermann</surname><given-names>DH</given-names></name><name><surname>Davis</surname><given-names>SN</given-names></name></person-group>:
<article-title>Effects of antecedent prolonged exercise on subsequent counterregulatory responses to hypoglycemia</article-title>.
<source>Am J Physiol Endocrinol Metab</source><year>2001</year>;
<volume>280</volume>:
<fpage>E908</fpage>&#x02013;
<lpage>E917</lpage><pub-id pub-id-type="pmid">11350772</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>SN</given-names></name><name><surname>Shavers</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name><name><surname>Mosqueda-Garcia</surname><given-names>R</given-names></name></person-group>:
<article-title>Role of cortisol in the pathogenesis of deficient count regulation after antecedent hypoglycemia in normal humans</article-title>.
<source>J Clin Invest</source><year>1996</year>;
<volume>98</volume>:
<fpage>680</fpage>&#x02013;
<lpage>691</lpage><pub-id pub-id-type="pmid">8698859</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGregor</surname><given-names>VP</given-names></name><name><surname>Banarer</surname><given-names>S</given-names></name><name><surname>Cryer</surname><given-names>PE</given-names></name></person-group>:
<article-title>Elevated endogenous cortisol reduces autonomic neuroendocrine and symptom responses to subsequent hypoglycemia</article-title>.
<source>Am J Physiol</source><year>2002</year>;
<volume>282</volume>:
<fpage>E770</fpage>&#x02013;
<lpage>E777</lpage></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamberts</surname><given-names>SW</given-names></name><name><surname>de Quijada</surname><given-names>M</given-names></name><name><surname>Visser</surname><given-names>TJ</given-names></name></person-group>:
<article-title>Regulation of prolactin secretion in patients with Cushing's disease. A comparative study on the effects of dexamethasone, lysine vasopressin and ACTH on prolactin secretion by the rat pituitary gland in vitro</article-title>.
<source>Neuroendocrinology</source><year>1981</year>;
<volume>32</volume>:
<fpage>150</fpage>&#x02013;
<lpage>154</lpage><pub-id pub-id-type="pmid">6261178</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodt</surname><given-names>C</given-names></name><name><surname>Keyser</surname><given-names>B</given-names></name><name><surname>Molle</surname><given-names>M</given-names></name><name><surname>Fehm</surname><given-names>HL</given-names></name><name><surname>Elam</surname><given-names>M</given-names></name></person-group>:
<article-title>Acute suppression of muscle sympathetic nerve activity by hydrocortisone in humans</article-title>.
<source>Hypertension</source><year>2000</year>;
<volume>35</volume>:
<fpage>758</fpage>&#x02013;
<lpage>763</lpage><pub-id pub-id-type="pmid">10720591</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szemeredi</surname><given-names>K</given-names></name><name><surname>Bagdy</surname><given-names>G</given-names></name><name><surname>Stull</surname><given-names>R</given-names></name><name><surname>Calogero</surname><given-names>AE</given-names></name><name><surname>Kopin</surname><given-names>IJ</given-names></name><name><surname>Goldstein</surname><given-names>DS</given-names></name></person-group>:
<article-title>Sympathoadrenomedullary inhibition by chronic glucocorticoid treatment in conscious rats</article-title>.
<source>Endocrinology</source><year>1988</year>;
<volume>123</volume>:
<fpage>2585</fpage>&#x02013;
<lpage>2590</lpage><pub-id pub-id-type="pmid">3168935</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golczynska</surname><given-names>A</given-names></name><name><surname>Lenders</surname><given-names>JW</given-names></name><name><surname>Goldstein</surname><given-names>DS</given-names></name></person-group>:
<article-title>Glucocorticoid-induced sympathoinhibition in humans</article-title>.
<source>Clin Pharmacol Ther</source><year>1995</year>;
<volume>58</volume>:
<fpage>90</fpage>&#x02013;
<lpage>98</lpage><pub-id pub-id-type="pmid">7628186</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheuer</surname><given-names>D</given-names></name><name><surname>Mifflin</surname><given-names>S</given-names></name></person-group>:
<article-title>Glucocorticoids modulate baroreflex control of renal sympathetic nerve activity</article-title>.
<source>Am J Physiol Regul Integr Comp Physiol</source><year>2001</year>;
<volume>280</volume>:
<fpage>R1440</fpage>&#x02013;
<lpage>R1449</lpage><pub-id pub-id-type="pmid">11294766</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flugge</surname><given-names>G</given-names></name></person-group>:
<article-title>Effects of cortisol on brain alpha2-adrenoceptors: potential role in stress</article-title>.
<source>Neurosci Biobehav Rev</source><year>1999</year>;
<volume>23</volume>:
<fpage>949</fpage>&#x02013;
<lpage>956</lpage><pub-id pub-id-type="pmid">10580309</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>SN</given-names></name><name><surname>Shavers</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name></person-group>:
<article-title>Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses</article-title>.
<source>J Clin Invest</source><year>1997</year>;
<volume>100</volume>:
<fpage>429</fpage>&#x02013;
<lpage>438</lpage><pub-id pub-id-type="pmid">9218521</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mion</surname><given-names>D</given-names><suffix>Jr</suffix></name><name><surname>Rea</surname><given-names>RF</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>Kahn</surname><given-names>D</given-names></name><name><surname>Sinkey</surname><given-names>C</given-names></name><name><surname>Mark</surname><given-names>A</given-names></name></person-group>:
<article-title>Effects of fludrocortisone on sympathetic nerve activity in humans</article-title>.
<source>Hypertension</source><year>1994</year>;
<volume>23</volume>:
<fpage>123</fpage>&#x02013;
<lpage>130</lpage><pub-id pub-id-type="pmid">8282323</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komesaroft</surname><given-names>PA</given-names></name><name><surname>Funder</surname><given-names>JW</given-names></name></person-group>:
<article-title>Differential glucocorticoid effects on catecholamine responses to stress</article-title>.
<source>Am J Physiol</source><year>1994</year>;
<volume>268</volume>:
<fpage>E118</fpage>&#x02013;
<lpage>E128</lpage></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>NM</given-names></name><name><surname>Ritter</surname><given-names>S</given-names></name></person-group>:
<article-title>Acute 2DG-induced glucoprivation or dexamethasone abolishes 2DG-induced glucoregulatory responses to subsequent glucoprivation</article-title>.
<source>Diabetes</source><year>2001</year>;
<volume>50</volume>:
<fpage>2831</fpage>&#x02013;
<lpage>2836</lpage><pub-id pub-id-type="pmid">11723067</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoval</surname><given-names>D</given-names></name><name><surname>Ping</surname><given-names>L</given-names></name><name><surname>Neil</surname><given-names>A</given-names></name><name><surname>Morrey</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>SN</given-names></name></person-group>:
<article-title>Cortisol acts through central mechanisms to blunt counterregulatory responses to hypoglycemia in conscious rats</article-title>.
<source>Diabetes</source><year>2003</year>;
<volume>52</volume>:
<fpage>2198</fpage>&#x02013;
<lpage>2204</lpage><pub-id pub-id-type="pmid">12941757</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MR</given-names></name><name><surname>Fisher</surname><given-names>J</given-names></name></person-group>:
<article-title>Glucocorticoid suppression of the sympathetic nervous system and adrenal medulla</article-title>.
<source>Life Sci</source><year>1986</year>;
<volume>39</volume>:
<fpage>1003</fpage>&#x02013;
<lpage>1012</lpage><pub-id pub-id-type="pmid">3018404</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tataranni</surname><given-names>PA</given-names></name><name><surname>Larson</surname><given-names>DE</given-names></name><name><surname>Snikter</surname><given-names>S</given-names></name><name><surname>Ravusin</surname><given-names>E</given-names></name></person-group>:
<article-title>The effects of glucocorticoids in energy metabolism and food intake in humans</article-title>.
<source>Am J Physiol</source><year>1996</year>;
<volume>271</volume>:
<fpage>E317</fpage>&#x02013;
<lpage>E325</lpage><pub-id pub-id-type="pmid">8770026</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kale</surname><given-names>AY</given-names></name><name><surname>Paranjape</surname><given-names>S</given-names></name><name><surname>Briski</surname><given-names>KP</given-names></name></person-group>:
<article-title>I.c.v. administration of the nonsteroidal glucocorticoid receptor antagonist, CP-472555, prevents exacerbated hypoglycemia during repeated insulin administration</article-title>.
<source>Neuroscience</source><year>2006</year>;
<volume>140</volume>:
<fpage>555</fpage>&#x02013;
<lpage>565</lpage><pub-id pub-id-type="pmid">16626867</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raju</surname><given-names>B</given-names></name><name><surname>McGregor</surname><given-names>VP</given-names></name><name><surname>Cryer</surname><given-names>PE</given-names></name></person-group>:
<article-title>Cortisol elevations comparable to those that occur during hypoglycemia do not cause hypoglycemia-associated autonomic failure</article-title>.
<source>Diabetes</source><year>2003</year>;
<volume>52</volume>:
<fpage>2083</fpage>&#x02013;
<lpage>2089</lpage><pub-id pub-id-type="pmid">12882926</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>P</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>McCrimmon</surname><given-names>R</given-names></name><name><surname>Hintz</surname><given-names>E</given-names></name><name><surname>Dziura</surname><given-names>J</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name></person-group>:
<article-title>Antecedent hypercortisolemia is not primarily responsible for generating hypoglycemia-associated autonomic failure</article-title>.
<source>Diabetes</source><year>2006</year>;
<volume>55</volume>:
<fpage>1121</fpage>&#x02013;
<lpage>1126</lpage><pub-id pub-id-type="pmid">16567537</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasserman</surname><given-names>K</given-names></name></person-group>:
<article-title>The anaerobic threshold measurement to evaluate exercise performance</article-title>.
<source>Am Rev Resp Dis</source><year>1984</year>;
<volume>129</volume>:
<fpage>535</fpage>&#x02013;
<lpage>540</lpage></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abumrad</surname><given-names>NN</given-names></name><name><surname>Rubin</surname><given-names>D</given-names></name><name><surname>Diamond</surname><given-names>MC</given-names></name><name><surname>Lacy</surname><given-names>WW</given-names></name></person-group>:
<article-title>Use of a heated superficial hand vein as an alternative site for measurement of amino acid concentration and for the study of glucose and alanine kinetics in man</article-title>.
<source>Metabolism</source><year>1981</year>;
<volume>30</volume>:
<fpage>936</fpage>&#x02013;
<lpage>940</lpage><pub-id pub-id-type="pmid">7022111</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Tobin</surname><given-names>K</given-names></name><name><surname>Andres</surname><given-names>R</given-names></name></person-group>:
<article-title>Glucose clamp technique: a method for quantifying insulin secretion and resistance</article-title>.
<source>Am J Physiol</source><year>1979</year>;
<volume>237</volume>:
<fpage>E216</fpage>&#x02013;
<lpage>E223</lpage></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>JS</given-names></name><name><surname>Steele</surname><given-names>R</given-names></name><name><surname>DeBodo</surname><given-names>RD</given-names></name><name><surname>Altszuler</surname><given-names>N</given-names></name></person-group>:
<article-title>Effect of insulin on utilization and production of circulating glucose</article-title>.
<source>Am J Physiol</source><year>1957</year>;
<volume>189</volume>:
<fpage>43</fpage>&#x02013;
<lpage>50</lpage><pub-id pub-id-type="pmid">13424687</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar-Parada</surname><given-names>E</given-names></name><name><surname>Eisentraut</surname><given-names>AM</given-names></name><name><surname>Unger</surname><given-names>RH</given-names></name></person-group>:
<article-title>Pancreatic glucagon secretion in normal and diabetic subjects</article-title>.
<source>Am J Med Sci</source><year>1969</year>;
<volume>257</volume>:
<fpage>415</fpage>&#x02013;
<lpage>419</lpage><pub-id pub-id-type="pmid">4893149</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanning</surname><given-names>I</given-names></name><name><surname>Home</surname><given-names>PD</given-names></name><name><surname>Alberti</surname><given-names>KG</given-names></name></person-group>:
<article-title>Measurement of free insulin concentrations: the influence of the timing of extraction of insulin antibodies</article-title>.
<source>Diabetologia</source><year>1985</year>;
<volume>28</volume>:
<fpage>831</fpage>&#x02013;
<lpage>835</lpage><pub-id pub-id-type="pmid">3910494</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Causon</surname><given-names>R</given-names></name><name><surname>Caruthers</surname><given-names>M</given-names></name><name><surname>Rodnight</surname><given-names>R</given-names></name></person-group>:
<article-title>Assay of plasma catecholamines by liquid chromatography with electrical detection</article-title>.
<source>Anal Biochem</source><year>1981</year>;
<volume>116</volume>:
<fpage>223</fpage>&#x02013;
<lpage>226</lpage><pub-id pub-id-type="pmid">7304981</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>W</given-names></name><name><surname>Greenwood</surname><given-names>F</given-names></name></person-group>:
<article-title>Preparation of [131I]-labeled human growth hormone of high specific activity</article-title>.
<source>Nature</source><year>1962</year>;
<volume>194</volume>:
<fpage>495</fpage>&#x02013;
<lpage>496</lpage><pub-id pub-id-type="pmid">14450081</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagopian</surname><given-names>W</given-names></name><name><surname>Lever</surname><given-names>E</given-names></name><name><surname>Cen</surname><given-names>D</given-names></name><name><surname>Emmounoud</surname><given-names>D</given-names></name><name><surname>Polonsky</surname><given-names>K</given-names></name><name><surname>Pugh</surname><given-names>W</given-names></name><name><surname>Moosa</surname><given-names>A</given-names></name><name><surname>Jaspan</surname><given-names>JB</given-names></name></person-group>:
<article-title>Predominance of renal and absence of hepatic metabolism of pancreatic polypeptide in the dog</article-title>.
<source>Am J Physiol</source><year>1983</year>;
<volume>245</volume>:
<fpage>171</fpage>&#x02013;
<lpage>177</lpage></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd</surname><given-names>B</given-names></name><name><surname>Burrin</surname><given-names>J</given-names></name><name><surname>Smythe</surname><given-names>P</given-names></name><name><surname>Alberti</surname><given-names>KGMM</given-names></name></person-group>:
<article-title>Enzymatic fluorometric continuous-flow assays for blood glucose lactate, pyruvate, alanine, glycerol, 3-hydroxybutyrate</article-title>.
<source>Clin Chem</source><year>1978</year>;
<volume>24</volume>:
<fpage>1724</fpage>&#x02013;
<lpage>1729</lpage><pub-id pub-id-type="pmid">699277</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>RJ</given-names></name></person-group>:
<article-title>Radiochemical assay of long chain fatty acid using 63NI as tracer</article-title>.
<source>Anal Biochem</source><year>1970</year>;
<volume>26</volume>:
<fpage>105</fpage>&#x02013;
<lpage>113</lpage><pub-id pub-id-type="pmid">5482617</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deary</surname><given-names>L</given-names></name><name><surname>Hepburn</surname><given-names>D</given-names></name><name><surname>Macleod</surname><given-names>K</given-names></name><name><surname>Frier</surname><given-names>BM</given-names></name></person-group>:
<article-title>Partitioning the symptoms of hypoglycemia using multi-sample confirmatory factor analysis</article-title>.
<source>Diabetologia</source><year>1993</year>;
<volume>36</volume>:
<fpage>771</fpage>&#x02013;
<lpage>777</lpage><pub-id pub-id-type="pmid">8405746</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younk</surname><given-names>L</given-names></name><name><surname>Tate</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>SN</given-names></name></person-group>:
<article-title>Physical activity in adolescents with type 1 diabetes: is more better for glycemic control?</article-title><source>Pediatric Diabetes</source><year>2009</year>;
<volume>10</volume>:
<fpage>231</fpage>&#x02013;
<lpage>233</lpage><pub-id pub-id-type="pmid">19493246</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGregor</surname><given-names>VP</given-names></name><name><surname>Greiwe</surname><given-names>JS</given-names></name><name><surname>Banarer</surname><given-names>S</given-names></name><name><surname>Cryer</surname><given-names>P</given-names></name></person-group>:
<article-title>Limited impact of vigorous exercise on defenses against hypoglycemia: relevance to hypoglycemia-associated autonomic failure (Abstract)</article-title>.
<source>Diabetes</source><year>2001</year>;
<volume>40</volume>(
<issue>Suppl. 2</issue>):
<fpage>A138</fpage></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisquolo</surname><given-names>V</given-names></name><name><surname>Cardoso</surname><given-names>C</given-names></name><name><surname>Ortega</surname><given-names>K</given-names></name><name><surname>Mion</surname><given-names>D</given-names></name><name><surname>Forjac</surname><given-names>C</given-names></name></person-group>:
<article-title>Previous exercise attenuates muscle sympathetic activity and increases blood flow during acute euglycemic hyperinsulinemia</article-title>.
<source>J Appl Physiol</source><year>2005</year>;
<volume>98</volume>:
<fpage>866</fpage>&#x02013;
<lpage>871</lpage><pub-id pub-id-type="pmid">15542577</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wasserman</surname><given-names>DH</given-names></name></person-group>:
<article-title>Control of glucose fluxes during exercise in the postabsorptive state</article-title>. In
<source><italic>Annual Review Physiology</italic></source>
<publisher-loc>Palo Alto, CA</publisher-loc>,
<publisher-name>Annual Reviews Inc.</publisher-name>,
<year>1995</year>, p.
<fpage>191</fpage>&#x02013;
<lpage>218</lpage></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabasa-Lhoret</surname><given-names>R</given-names></name><name><surname>Bourque</surname><given-names>J</given-names></name><name><surname>Ducros</surname><given-names>F</given-names></name><name><surname>Chiasson</surname><given-names>JL</given-names></name></person-group>:
<article-title>Guldelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro)</article-title>.
<source>Diabetes Care</source><year>2001</year>;
<volume>24</volume>:
<fpage>625</fpage>&#x02013;
<lpage>630</lpage><pub-id pub-id-type="pmid">11315820</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>J</given-names></name><name><surname>Cardin</surname><given-names>S</given-names></name><name><surname>Doiron</surname><given-names>B</given-names></name></person-group>:
<article-title>Influence of hepatic vagus nerve on pancreatic hormone secretion during exercise</article-title>.
<source>Am J Physiol</source><year>1989</year>;
<volume>257</volume>:
<fpage>E855</fpage>&#x02013;
<lpage>E859</lpage><pub-id pub-id-type="pmid">2692457</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjaer</surname><given-names>M</given-names></name><name><surname>Engfred</surname><given-names>K</given-names></name><name><surname>Fernandes</surname><given-names>A</given-names></name><name><surname>Secher</surname><given-names>NH</given-names></name><name><surname>Galbo</surname><given-names>H</given-names></name></person-group>:
<article-title>Regulation of hepatic glucose production during exercise in humans: role of sympathoadrenergic activity</article-title>.
<source>Am J Physiol</source><year>1993</year>;
<volume>265</volume>:
<fpage>E275</fpage>&#x02013;
<lpage>E283</lpage><pub-id pub-id-type="pmid">8368297</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>D</given-names></name><name><surname>Floyd</surname><given-names>JC</given-names></name><name><surname>Lampman</surname><given-names>RM</given-names></name><name><surname>Fojans</surname><given-names>SS</given-names></name></person-group>:
<article-title>The effect of adrenergic receptor blockade on the exercise-induced rise in pancreatic polypeptide in man</article-title>.
<source>J Clin Endocrinol Metab</source><year>1980</year>;
<volume>50</volume>:
<fpage>33</fpage>&#x02013;
<lpage>39</lpage><pub-id pub-id-type="pmid">7350185</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>B</given-names></name><name><surname>Marklund</surname><given-names>S</given-names></name><name><surname>Steiler</surname><given-names>TL</given-names></name><name><surname>Walter</surname><given-names>M</given-names></name><name><surname>Hjalm</surname><given-names>G</given-names></name><name><surname>Amarger</surname><given-names>V</given-names></name><name><surname>Mahlapuu</surname><given-names>M</given-names></name><name><surname>Leng</surname><given-names>Y</given-names></name><name><surname>Johansson</surname><given-names>C</given-names></name><name><surname>Galuska</surname><given-names>D</given-names></name><name><surname>Lindgren</surname><given-names>K</given-names></name><name><surname>Abrink</surname><given-names>M</given-names></name><name><surname>Stapleton</surname><given-names>D</given-names></name><name><surname>Zierath</surname><given-names>JR</given-names></name><name><surname>Andersson</surname><given-names>L</given-names></name></person-group>:
<article-title>The 5&#x02033;-AMP-activated protein kinase &#x003b3;3 Isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle</article-title>.
<source>J Biol Chem</source><year>2004</year>;
<volume>279</volume>:
<fpage>38441</fpage>&#x02013;
<lpage>38447</lpage><pub-id pub-id-type="pmid">15247217</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCrimmon</surname><given-names>RJ</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>McNay</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>O</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Sherviwn</surname><given-names>RS</given-names></name></person-group>:
<article-title>Activation of AMP-activated protein kinase within the ventromedial hypothalamus amplifies counterregulatory hormone responses in rats with defective counterregulation</article-title>.
<source>Diabetes</source><year>2006</year>;
<volume>55</volume>:
<fpage>1755</fpage>&#x02013;
<lpage>1760</lpage><pub-id pub-id-type="pmid">16731839</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCrimmon</surname><given-names>RJ</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Jacob</surname><given-names>RJ</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name></person-group>:
<article-title>Potential role for AMP-activated protein kinase in hypoglycemia sensing in the ventromedial hypothalamus</article-title>.
<source>Diabetes</source><year>2004</year>;
<volume>53</volume>:
<fpage>1953</fpage>&#x02013;
<lpage>1958</lpage><pub-id pub-id-type="pmid">15277372</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kola</surname><given-names>B</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Lolli</surname><given-names>F</given-names></name><name><surname>Arnaldi</surname><given-names>G</given-names></name><name><surname>Giacchetti</surname><given-names>G</given-names></name><name><surname>Boscaro</surname><given-names>M</given-names></name><name><surname>Grossman</surname><given-names>A</given-names></name><name><surname>Korbonits</surname><given-names>M</given-names></name></person-group>:
<article-title>Changes in adenosine 5&#x02032;-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's Syndrome</article-title>.
<source>J Clin Endocrinol Metab</source><year>2008</year>;
<volume>93</volume>:
<fpage>4969</fpage>&#x02013;
<lpage>4973</lpage><pub-id pub-id-type="pmid">18782871</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Yamaguchi-Shima</surname><given-names>N</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>J</given-names></name><name><surname>Yorimitsu</surname><given-names>M</given-names></name><name><surname>Yokotani</surname><given-names>K</given-names></name></person-group>:
<article-title>Centrally administered N-methyl-D-aspartate evokes the adrenal secretion of noradrenaline and adrenaline by brain thromboxane A2-mediated mechanisms in rats</article-title>.
<source>Eur J Pharmacol</source><year>2008</year>;
<volume>586</volume>:
<fpage>145</fpage>&#x02013;
<lpage>150</lpage><pub-id pub-id-type="pmid">18374330</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Ni</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group>:
<article-title>A rapid inhibition of NMDA receptor current by corticosterone in cultured hippocampal neurons</article-title>.
<source>Neuro Sci Lett</source><year>2007</year>;
<volume>420</volume>:
<fpage>245</fpage>&#x02013;
<lpage>250</lpage></mixed-citation></ref></ref-list></back></article>